Quest Diagnostics Price to Sales Ratio 2012-2026 | DGX
Historical PS ratio values for Quest Diagnostics (DGX) over the last 10 years. The current P/S ratio for Quest Diagnostics as of September 16, 2026 is .
| Quest Diagnostics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-17 | 247.45 | 2.41 | |
| 2026-06-30 | 211.09 | $102.77 | 2.05 |
| 2026-03-31 | 194.34 | $100.03 | 1.94 |
| 2025-12-31 | 171.30 | $97.65 | 1.75 |
| 2025-09-30 | 187.30 | $96.02 | 1.95 |
| 2025-06-30 | 175.74 | $93.12 | 1.89 |
| 2025-03-31 | 164.73 | $90.08 | 1.83 |
| 2024-12-31 | 146.16 | $87.74 | 1.67 |
| 2024-09-30 | 149.67 | $84.79 | 1.77 |
| 2024-06-30 | 131.25 | $82.91 | 1.58 |
| 2024-03-31 | 126.91 | $82.01 | 1.55 |
| 2023-12-31 | 130.77 | $81.52 | 1.60 |
| 2023-09-30 | 114.91 | $81.04 | 1.42 |
| 2023-06-30 | 131.86 | $81.98 | 1.61 |
| 2023-03-31 | 132.07 | $82.08 | 1.61 |
| 2022-12-31 | 145.38 | $83.03 | 1.75 |
| 2022-09-30 | 113.40 | $84.70 | 1.34 |
| 2022-06-30 | 122.32 | $85.82 | 1.43 |
| 2022-03-31 | 124.68 | $85.29 | 1.46 |
| 2021-12-31 | 156.92 | $83.86 | 1.87 |
| 2021-09-30 | 131.23 | $84.49 | 1.55 |
| 2021-06-30 | 118.63 | $82.64 | 1.44 |
| 2021-03-31 | 114.81 | $75.99 | 1.51 |
| 2020-12-31 | 106.13 | $69.34 | 1.53 |
| 2020-09-30 | 101.46 | $61.43 | 1.65 |
| 2020-06-30 | 100.51 | $55.37 | 1.82 |
| 2020-03-31 | 70.28 | $56.30 | 1.25 |
| 2019-12-31 | 93.01 | $56.70 | 1.64 |
| 2019-09-30 | 92.75 | $55.77 | 1.66 |
| 2019-06-30 | 87.77 | $55.08 | 1.59 |
| 2019-03-31 | 77.07 | $54.53 | 1.41 |
| 2018-12-31 | 70.93 | $54.18 | 1.31 |
| 2018-09-30 | 91.48 | $54.27 | 1.69 |
| 2018-06-30 | 92.78 | $53.94 | 1.72 |
| 2018-03-31 | 84.21 | $53.45 | 1.58 |
| 2017-12-31 | 82.32 | $52.78 | 1.56 |
| 2017-09-30 | 77.89 | $50.44 | 1.54 |
| 2017-06-30 | 92.09 | $50.46 | 1.82 |
| 2017-03-31 | 80.97 | $50.57 | 1.60 |
| 2016-12-31 | 75.42 | $50.62 | 1.49 |
| 2016-09-30 | 69.45 | $52.39 | 1.33 |
| 2016-06-30 | 66.16 | $52.08 | 1.27 |
| 2016-03-31 | 57.75 | $51.93 | 1.11 |
| 2015-12-31 | 57.18 | $51.59 | 1.11 |
| 2015-09-30 | 49.10 | $51.82 | 0.95 |
| 2015-06-30 | 57.62 | $51.99 | 1.11 |
| 2015-03-31 | 60.75 | $51.83 | 1.17 |
| 2014-12-31 | 52.76 | $51.28 | 1.03 |
| 2014-09-30 | 47.48 | $49.77 | 0.95 |
| 2014-06-30 | 45.67 | $48.48 | 0.94 |
| 2014-03-31 | 44.83 | $47.15 | 0.95 |
| 2013-12-31 | 41.20 | $46.34 | 0.89 |
| 2013-09-30 | 47.55 | $45.95 | 1.03 |
| 2013-06-30 | 46.43 | $45.45 | 1.02 |
| 2013-03-31 | 43.03 | $45.42 | 0.95 |
| 2012-12-31 | 43.94 | $46.13 | 0.95 |
| 2012-09-30 | 47.83 | $46.05 | 1.04 |
| 2012-06-30 | 45.05 | $46.70 | 0.96 |
| 2012-03-31 | 45.86 | $46.89 | 0.98 |
| 2011-12-31 | 43.29 | $46.22 | 0.94 |
| 2011-09-30 | 36.73 | $44.89 | 0.82 |
| 2011-06-30 | 43.97 | $43.59 | 1.01 |
| 2011-03-31 | 42.80 | $42.02 | 1.02 |
| 2010-12-31 | 39.95 | $40.64 | 0.98 |
| 2010-09-30 | 37.36 | $40.81 | 0.92 |
| 2010-06-30 | 36.69 | $40.25 | 0.91 |
| 2010-03-31 | 42.90 | $40.05 | 1.07 |
| 2009-12-31 | 44.36 | $39.63 | 1.12 |
| 2009-09-30 | 38.34 | $38.97 | 0.98 |
| 2009-06-30 | 41.31 | $38.10 | 1.08 |
| 2009-03-31 | 34.68 | $37.30 | 0.93 |
| 2008-12-31 | 37.84 | $36.94 | 1.02 |
| 2008-09-30 | 37.59 | $36.82 | 1.02 |
| 2008-06-30 | 35.19 | $36.59 | 0.96 |
| 2008-03-31 | 32.80 | $35.66 | 0.92 |
| 2007-12-31 | 38.25 | $34.36 | 1.11 |
| 2007-09-30 | 41.70 | $33.05 | 1.26 |
| 2007-06-30 | 37.21 | $31.93 | 1.17 |
| 2007-03-31 | 35.86 | $31.38 | 1.14 |
| 2006-12-31 | 38.03 | $31.29 | 1.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $27.271B | $11.035B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.874B | 13.39 |
| DaVita (DVA) | United States | $12.368B | 15.15 |
| Encompass Health (EHC) | United States | $12.224B | 21.22 |
| Elanco Animal Health (ELAN) | United States | $11.421B | 21.57 |
| Chemed (CHE) | United States | $6.665B | 23.76 |
| RadNet (RDNT) | United States | $5.964B | 172.23 |
| LifeStance Health (LFST) | United States | $4.888B | 98.39 |
| Option Care Health (OPCH) | United States | $3.665B | 15.49 |
| Aveanna Healthcare Holdings (AVAH) | United States | $3.112B | 21.61 |
| Addus HomeCare (ADUS) | United States | $2.213B | 20.02 |
| Astrana Health (ASTH) | United States | $2.101B | 22.31 |
| Pennant (PNTG) | United States | $1.484B | 38.62 |
| U.S Physical Therapy (USPH) | United States | $1.244B | 32.83 |
| Daxor (DXR) | United States | $0.068B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.022B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |